GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (LTS:0IIM) » Definitions » EBITDA Margin %

Esperion Therapeutics (LTS:0IIM) EBITDA Margin % : -27.92% (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Esperion Therapeutics EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Esperion Therapeutics's EBITDA for the three months ended in Sep. 2024 was $-14.4 Mil. Esperion Therapeutics's Revenue for the three months ended in Sep. 2024 was $51.6 Mil. Therefore, Esperion Therapeutics's EBITDA margin for the quarter that ended in Sep. 2024 was -27.92%.


Esperion Therapeutics EBITDA Margin % Historical Data

The historical data trend for Esperion Therapeutics's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics EBITDA Margin % Chart

Esperion Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -59.80 -52.88 -283.18 -233.65 -129.03

Esperion Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -77.21 -128.00 54.49 -65.27 -27.92

Competitive Comparison of Esperion Therapeutics's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Esperion Therapeutics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Esperion Therapeutics's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Esperion Therapeutics's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Esperion Therapeutics's EBITDA Margin % falls into.



Esperion Therapeutics EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Esperion Therapeutics's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-150.108/116.334
=-129.03 %

Esperion Therapeutics's EBITDA Margin % for the quarter that ended in Sep. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-14.416/51.632
=-27.92 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Esperion Therapeutics  (LTS:0IIM) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Esperion Therapeutics EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Esperion Therapeutics Business Description

Traded in Other Exchanges
Address
3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.

Esperion Therapeutics Headlines

No Headlines